Baird analyst Michael Ha said he is catiously optimistic on UnitedHealth (UNH) shares and maintains his Outperform rating and $640 price target ...
UnitedHealth's OptumRx to pass 100% of drug rebates to clients by 2028, but critics say GPO structure may still hide true ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback